Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Micafungin
Drug ID BADD_D01455
Description Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Indications and Usage For use in the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.
Marketing Status Prescription
ATC Code J02AX05
DrugBank ID DB01141
KEGG ID D08218
MeSH ID D000077551
PubChem ID 477468
TTD Drug ID D06TOE
NDC Product Code 60505-6119; 42023-229; 42023-230; 60505-6120
Synonyms Micafungin | FK 463 | FK463 | FK-463 | Micafungin Sodium | Mycamine
Chemical Information
Molecular Formula C56H71N9O23S
CAS Registry Number 235114-32-6
SMILES CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC (=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(C C(=O)N)O)C)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypomagnesaemia14.04.02.001--
Hyponatraemia14.05.04.0020.001057%
Hypophosphataemia14.04.03.001--
Hypotension24.06.03.002--
Hypoxia22.02.02.0030.001057%
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Injection site pain08.02.03.010; 12.07.03.011--Not Available
Injection site reaction08.02.03.014; 12.07.03.015--
Injection site thrombosis24.01.01.023; 12.07.03.028; 08.02.03.028--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
Leukopenia01.02.02.0010.000705%Not Available
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
Lymphopenia01.02.02.002--Not Available
Mucormycosis22.07.03.021; 11.03.05.011; 17.06.09.003; 07.05.07.0110.000276%Not Available
Mucosal inflammation08.01.06.002--Not Available
Muscle spasms15.05.03.0040.001057%
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Neoplasm malignant16.16.01.001--Not Available
Nephropathy20.05.03.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Neutropenia01.02.03.0040.001762%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oliguria20.01.03.004--Not Available
Osteolysis15.02.03.008; 14.04.04.0060.000705%Not Available
Palpitations02.01.02.003--
Pancytopenia01.03.03.003--Not Available
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages